{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:45:20Z","timestamp":1791067520612,"version":"4.1.0"},"reference-count":205,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T00:00:00Z","timestamp":1405036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100002555","name":"AIRC","doi-asserted-by":"publisher","award":["9970"],"award-info":[{"award-number":["9970"]}],"id":[{"id":"10.13039\/100002555","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AIRC Investigator Grants","award":["10116"],"award-info":[{"award-number":["10116"]}]},{"name":"AIRC Investigator Grants","award":["14205"],"award-info":[{"award-number":["14205"]}]},{"name":"Fondazione Piemontese per la Ricerca sul Cancro-ONLUS"},{"name":"5x1000 Ministero della Salute 2011"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.bbcan.2014.07.004","type":"journal-article","created":{"date-parts":[[2014,7,12]],"date-time":"2014-07-12T12:15:58Z","timestamp":1405167358000},"page":"201-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited"],"prefix":"10.1016","volume":"1846","author":[{"given":"Barbara","family":"Lupo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trusolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2014.07.004_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0006-291X(63)90024-X","article-title":"Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme","volume":"11","author":"Chambon","year":"1963","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0015","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA repair: additional functions of PARP-1 in cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tibs.2009.12.003","article-title":"Toward a unified nomenclature for mammalian ADP-ribosyltransferases","volume":"35","author":"Hottiger","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0076-6879(05)09029-4","article-title":"Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair","volume":"409","author":"Dantzer","year":"2006","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0035","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/emboj\/cdg206","article-title":"Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse","volume":"22","author":"M\u00e9nissier de Murcia","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0040","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1073\/pnas.1016574108","article-title":"Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression","volume":"108","author":"Boehler","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-33-19","article-title":"Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity","volume":"33","author":"Fern\u00e1ndez-Marcelo","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nrd3868","article-title":"Tankyrase-targeted therapeutics: expanding opportunities in the PARP family","volume":"11","author":"Riffell","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0055","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/ncomms3240","article-title":"A systematic analysis of the PARP protein family identifies new functions critical for cell physiology","volume":"4","author":"Vyas","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0060","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0070","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1244669","article-title":"Cancer. Potential of the synthetic lethality principle","volume":"342","author":"Nijman","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","article-title":"Targeted therapy for cancer using PARP inhibitors","volume":"8","author":"Lord","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0085","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0090","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.biochi.2003.11.003","article-title":"The base excision repair: mechanisms and its relevance for cancer susceptibility","volume":"85","author":"Fortini","year":"2003","journal-title":"Biochimie"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrm3047","article-title":"The MRE11 complex: starting from the ends","volume":"12","author":"Stracker","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1101\/gad.2021311","article-title":"Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications","volume":"25","author":"Polo","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0115","first-page":"130","article-title":"DNA double strand break repair via non-homologous end-joining","volume":"2","author":"Davis","year":"2013","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art","volume":"84","author":"De Vos","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0125","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1111\/j.1742-4658.2005.04864.x","article-title":"Poly(ADP-ribose). The most elaborate metabolite of NAD+","volume":"272","author":"B\u00fcrkle","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0130","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Satoh","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0135","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1093\/nar\/gkg761","article-title":"A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage","volume":"31","author":"El-Khamisy","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0140","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1093\/nar\/24.22.4387","article-title":"XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular \u2018nick-sensor\u2019 in vitro","volume":"24","author":"Caldecott","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0145","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1093\/nar\/gkq1241","article-title":"Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate","volume":"39","author":"Str\u00f6m","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0150","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.dnarep.2011.08.012","article-title":"PARP-1 enhances the mismatch-dependence of 5\u2032-directed excision in human mismatch repair in vitro","volume":"10","author":"Liu","year":"2011","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0155","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1073\/pnas.1209507110","article-title":"Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair","volume":"110","author":"Robu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0160","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4161\/cc.4.9.2031","article-title":"Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy","volume":"4","author":"Helleday","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0165","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0170","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0175","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1074\/jbc.M710245200","article-title":"Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair","volume":"283","author":"Chen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0180","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.0811159106","article-title":"PALB2 is an integral component of the BRCA complex required for homologous recombination repair","volume":"106","author":"Sy","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0185","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nsmb.1904","article-title":"Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA","volume":"17","author":"Liu","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0190","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/nar\/gkl010","article-title":"BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution","volume":"34","author":"Deng","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","article-title":"Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective","volume":"46","author":"Sandhu","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0200","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500904X","article-title":"PARP inhibitors for cancer therapy","volume":"7","author":"Curtin","year":"2005","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pharmthera.2012.10.009","article-title":"Targeting DNA repair mechanisms in cancer","volume":"137","author":"Furgason","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0215","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0220","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gde.2008.01.016","article-title":"DNA repair deficiency as a therapeutic target in cancer","volume":"18","author":"Martin","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0230","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tips.2010.06.001","article-title":"Targeting homologous recombination repair defects in cancer","volume":"31","author":"Evers","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0235","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0240","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0250","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0255","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0260","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0265","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","article-title":"Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","volume":"10","author":"Dedes","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0270","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0275","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-10-1120","article-title":"MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers","volume":"71","author":"Vilar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0280","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1535-7163.MCT-12-0950","article-title":"RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib","volume":"12","author":"Min","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0285","article-title":"Predictive biomarkers for cancer therapy with PARP inhibitors","author":"Michels","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0290","doi-asserted-by":"crossref","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0295","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/0008-5472.CAN-09-4295","article-title":"PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors","volume":"70","author":"McEllin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0305","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrclinonc.2011.42","article-title":"Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer","volume":"8","author":"Forster","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0310","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0315","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1158\/1078-0432.CCR-11-2189","article-title":"PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy","volume":"18","author":"Fraser","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0320","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.4161\/cc.8.14.8947","article-title":"Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair","volume":"8","author":"Gupta","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0325","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-11-3131","article-title":"Does PTEN loss impair DNA double-strand break repair by homologous recombination?","volume":"18","author":"Hunt","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0330","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0335","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-10-0939","article-title":"Poly(ADP-ribose) polymerase inhibition: \u201ctargeted\u201d therapy for triple-negative breast cancer","volume":"16","author":"Anders","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0340","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/1471-2407-10-654","article-title":"BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations","volume":"10","author":"Holstege","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0345","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0350","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/MCB.23.7.2225-2238.2003","article-title":"Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma","volume":"23","author":"Baldassarre","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0355","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1073\/pnas.98.1.130","article-title":"Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach","volume":"98","author":"Beger","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0360","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0365","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1634\/theoncologist.2013-0039","article-title":"Differential chemotherapeutic sensitivity for breast tumors with \u201cBRCAness\u201d: a review","volume":"18","author":"Chalasani","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0370","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","article-title":"EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer","volume":"115","author":"Hughes-Davies","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0375","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"C.G.A.R. Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0380","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","article-title":"BRCAness: finding the Achilles heel in ovarian cancer","volume":"17","author":"Rigakos","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0385","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3390\/biom2040635","article-title":"Strategies for the use of poly(adenosine diphosphate ribose) polymerase (PARP) Inhibitors in cancer therapy","volume":"2","author":"Str\u00f6m","year":"2012","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/283593a0","article-title":"(ADP-ribose)n participates in DNA excision repair","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0395","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0400","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jnci\/djh005","article-title":"Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361","volume":"96","author":"Calabrese","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0405","first-page":"5370","article-title":"Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma","volume":"9","author":"Tentori","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0410","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0415","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0420","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","article-title":"Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors","volume":"14","author":"Plummer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0425","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0430","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0435","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","article-title":"A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors","volume":"18","author":"Rajan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0440","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/bjc.2011.8","article-title":"A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours","volume":"104","author":"Khan","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0445","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10637-011-9682-9","article-title":"Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study","volume":"30","author":"Samol","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0450","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0455","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0460","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0465","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2013.00301","article-title":"Structural implications for selective targeting of PARPs","volume":"3","author":"Steffen","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0470","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0475","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0485","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0490","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O'Shaughnessy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0495","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.1007","article-title":"A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (G\/C) in metastatic triple-negative breast cancer (TNBC)","volume":"29","author":"O'Shaughnessy","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0500","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-11-2890","article-title":"Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro","volume":"18","author":"Patel","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0505","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0510","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0515","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0520","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","article-title":"Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer","volume":"19","author":"Brenner","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0525","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1535-7163.MCT-08-0959","article-title":"Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity","volume":"8","author":"Choudhury","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0530","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1158\/1078-0432.CCR-07-1610","article-title":"The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage","volume":"13","author":"Chen","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0535","doi-asserted-by":"crossref","first-page":"9141","DOI":"10.1158\/0008-5472.CAN-08-1127","article-title":"Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0540","doi-asserted-by":"crossref","first-page":"e46614","DOI":"10.1371\/journal.pone.0046614","article-title":"Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells","volume":"7","author":"Nowsheen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0545","doi-asserted-by":"crossref","first-page":"e24148","DOI":"10.1371\/journal.pone.0024148","article-title":"Cetuximab augments cytotoxicity with poly (ADP-ribose) polymerase inhibition in head and neck cancer","volume":"6","author":"Nowsheen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0550","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1158\/0008-5472.CAN-13-0044","article-title":"EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity","volume":"73","author":"Pf\u00e4ffle","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0555","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1158\/0008-5472.CAN-12-1287","article-title":"HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair","volume":"72","author":"Nowsheen","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0560","doi-asserted-by":"crossref","first-page":"pe15","DOI":"10.1126\/scisignal.2001946","article-title":"MYC, PARP1, and chemoresistance: BIN there, done that?","volume":"4","author":"Ganesan","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0565","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0570","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","article-title":"A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer","volume":"49","author":"Liu","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0575","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2011.555","article-title":"Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours","volume":"106","author":"Dean","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0580","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molonc.2012.01.011","article-title":"The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities","volume":"6","author":"De Palma","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0585","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0590","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-13-0225","article-title":"Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?","volume":"20","author":"Bouwman","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0595","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0600","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0605","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0610","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0615","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1158\/0008-5472.CAN-08-2287","article-title":"Drug resistance caused by reversion mutation","volume":"68","author":"Ashworth","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0620","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1158\/0008-5472.CAN-09-3416","article-title":"6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance","volume":"70","author":"Issaeva","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0625","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0630","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0635","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jmcb\/mjq055","article-title":"BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability","volume":"3","author":"Aly","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0640","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0645","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2012.12.007","article-title":"53BP1 expression in sporadic and inherited ovarian carcinoma: relationship to genetic status and clinical outcomes","volume":"128","author":"Pennington","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0650","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","article-title":"BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance","volume":"20","author":"Drost","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0655","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0959-437X(96)80091-8","article-title":"P-glycoprotein and multidrug resistance","volume":"6","author":"Gottesman","year":"1996","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0660","first-page":"4238","article-title":"Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein","volume":"60","author":"Wurzer","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0665","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0670","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tips.2011.10.001","article-title":"A snapshot of chemoresistance to PARP inhibitors","volume":"33","author":"Chiarugi","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0675","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0680","doi-asserted-by":"crossref","first-page":"e61520","DOI":"10.1371\/journal.pone.0061520","article-title":"A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity","volume":"8","author":"Pettitt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0685","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0117-z","article-title":"Prediction of BRCA1-association in hereditary non-BRCA1\/2 breast carcinomas with array-CGH","volume":"116","author":"Joosse","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0690","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0695","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0700","doi-asserted-by":"crossref","first-page":"e30042","DOI":"10.1371\/journal.pone.0030042","article-title":"BRCAness profile of sporadic ovarian cancer predicts disease recurrence","volume":"7","author":"Wysham","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0705","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1158\/1078-0432.CCR-13-1975","article-title":"Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer","volume":"19","author":"Cardnell","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0710","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0715","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1541-7786.MCR-09-0149","article-title":"Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies","volume":"7","author":"Willers","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0720","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0725","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"Mukhopadhyay","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0730","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4161\/cc.22026","article-title":"Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment","volume":"11","author":"Oplustilova","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0735","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-10-0523","article-title":"Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers","volume":"16","author":"Redon","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0740","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-050311-163404","article-title":"Circulating tumor cells: from bench to bedside","volume":"64","author":"Balic","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0745","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.20095","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic","volume":"61","author":"Yap","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0750","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/0008-5472.CAN-09-4716","article-title":"Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells","volume":"70","author":"Gottipati","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0755","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-011-1375-8","article-title":"Biomarkers of PARP inhibitor sensitivity","volume":"127","author":"Turner","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0760","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.mam.2013.01.005","article-title":"PARP-1 and gene regulation: progress and puzzles","volume":"34","author":"Kraus","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0765","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/embor.2008.191","article-title":"The expanding field of poly(ADP-ribosyl)ation reactions. \u2018Protein modifications: beyond the usual suspects\u2019 review series","volume":"9","author":"Hakm\u00e9","year":"2008","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0770","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0775","first-page":"113","article-title":"Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34","volume":"22","author":"Pyriochou","year":"2008","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0780","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.bbrc.2006.09.049","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0785","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis","volume":"43","author":"Tentori","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0790","first-page":"861","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells","volume":"34","author":"Lacal","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0795","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ejca.2008.03.019","article-title":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity","volume":"44","author":"Tentori","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0800","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/onc.2011.153","article-title":"Poly(ADP-ribose)-dependent regulation of Snail1 protein stability","volume":"30","author":"Rodr\u00edguez","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0805","doi-asserted-by":"crossref","first-page":"e1003531","DOI":"10.1371\/journal.pgen.1003531","article-title":"PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation","volume":"9","author":"Rodr\u00edguez","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0810","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-05-3050","article-title":"Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis","volume":"66","author":"Martin-Oliva","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0815","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/ncomms2672","article-title":"Regulation of NF-\u03baB signalling by the mono-ADP-ribosyltransferase ARTD10","volume":"4","author":"Verheugd","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0820","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cell.2004.11.017","article-title":"Activating the PARP-1 sensor component of the groucho\/TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway","volume":"119","author":"Ju","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0825","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1128\/MCB.19.1.296","article-title":"Poly(ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription","volume":"19","author":"Butler","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0830","doi-asserted-by":"crossref","first-page":"40450","DOI":"10.1074\/jbc.M507553200","article-title":"Acetylation of poly(ADP-ribose) polymerase-1 by p300\/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription","volume":"280","author":"Hassa","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0835","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/rna.19899","article-title":"Poly(ADP-ribose) regulates post-transcriptional gene regulation in the cytoplasm","volume":"9","author":"Leung","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0840","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/MMBR.00040-05","article-title":"Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?","volume":"70","author":"Hassa","year":"2006","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0845","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.mam.2013.01.004","article-title":"Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes","volume":"34","author":"Cant\u00f3","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0850","doi-asserted-by":"crossref","first-page":"ra20","DOI":"10.1126\/scisignal.2000902","article-title":"Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos)","volume":"4","author":"Wang","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0855","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/MCB.23.7.2451-2462.2003","article-title":"Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function","volume":"23","author":"Kanai","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0860","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1242\/jcs.00341","article-title":"PARP-3 localizes preferentially to the daughter centriole and interferes with the G1\/S cell cycle progression","volume":"116","author":"Augustin","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0865","doi-asserted-by":"crossref","first-page":"12975","DOI":"10.1074\/jbc.M111.321828","article-title":"CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation","volume":"287","author":"Kashima","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0870","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc1714","article-title":"On the road to cancer: aneuploidy and the mitotic checkpoint","volume":"5","author":"Kops","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0875","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/0008-5472.CAN-09-4224","article-title":"Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors","volume":"70","author":"Efimova","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0880","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tcb.2011.11.006","article-title":"Senescence: a new weapon for cancer therapy","volume":"22","author":"Acosta","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0885","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/mt.2012.19","article-title":"Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine","volume":"20","author":"Meng","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0890","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ncb1909","article-title":"Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion","volume":"11","author":"Rodier","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0895","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0960-9822(00)00752-1","article-title":"Tankyrase promotes telomere elongation in human cells","volume":"10","author":"Smith","year":"2000","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0900","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/MCB.22.1.332-342.2002","article-title":"Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres","volume":"22","author":"Cook","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0905","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2004.11.021","article-title":"Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics","volume":"7","author":"Seimiya","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0910","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1158\/0008-5472.CAN-10-2734","article-title":"High-throughput RNAi screening reveals novel regulators of telomerase","volume":"71","author":"Cerone","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0915","first-page":"1059","article-title":"Inhibition of tankyrase 1 in human gastric cancer cells enhances telomere shortening by telomerase inhibitors","volume":"24","author":"Zhang","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0920","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3892\/or.2013.2665","article-title":"Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation","volume":"30","author":"Lu","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0925","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ncb1322","article-title":"Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function","volume":"7","author":"Chang","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0930","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1091\/mbc.E09-06-0477","article-title":"Interaction between Poly(ADP-ribose) and NuMA contributes to mitotic spindle pole assembly","volume":"20","author":"Chang","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0935","doi-asserted-by":"crossref","DOI":"10.4161\/cc.27945","article-title":"ATM controls proper mitotic spindle structure","volume":"13","author":"Palazzo","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0940","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.1094754","article-title":"Resolution of sister telomere association is required for progression through mitosis","volume":"304","author":"Dynek","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0945","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1083\/jcb.200810132","article-title":"Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ","volume":"184","author":"Hsiao","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0950","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1091\/mbc.E13-08-0479","article-title":"Persistent telomere cohesion triggers a prolonged anaphase","volume":"25","author":"Kim","year":"2014","journal-title":"Mol. Biol. Cell"},{"issue":"Pt 21","key":"10.1016\/j.bbcan.2014.07.004_bb0955","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1242\/jcs.112.21.3649","article-title":"Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes","volume":"112","author":"Smith","year":"1999","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0960","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/embor.2012.86","article-title":"Tankyrase 1 regulates centrosome function by controlling CPAP stability","volume":"13","author":"Kim","year":"2012","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0965","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.molcel.2012.06.033","article-title":"Poly-ADP ribosylation of Miki by tankyrase-1 promotes centrosome maturation","volume":"47","author":"Ozaki","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0970","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/onc.2008.483","article-title":"Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer","volume":"28","author":"McCabe","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0975","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0980","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0985","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"C.G.A. Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2014.07.004_bb0990","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-12-4562","article-title":"A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth","volume":"73","author":"Lau","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb0995","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-11-3336","article-title":"A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice","volume":"72","author":"Waaler","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb1000","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/0008-5472.CAN-11-2848","article-title":"Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition","volume":"72","author":"Cas\u00e1s-Selves","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2014.07.004_bb1005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/BJ20060793","article-title":"Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase","volume":"402","author":"Yeh","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2014.07.004_bb1010","doi-asserted-by":"crossref","first-page":"691","DOI":"10.18632\/aging.100210","article-title":"Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs","volume":"2","author":"Dregalla","year":"2010","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bbcan.2014.07.004_bb1015","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.dnarep.2008.08.014","article-title":"A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity","volume":"7","author":"Lord","year":"2008","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbcan.2014.07.004_bb1020","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1111\/febs.12298","article-title":"PARP inhibitors: polypharmacology versus selective inhibition","volume":"280","author":"Ekblad","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2014.07.004_bb1025","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-13-1262","article-title":"Efficacy of chemotherapy in BRCA1\/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study","volume":"19","author":"Ang","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X14000572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X14000572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:03:27Z","timestamp":1649635407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X14000572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":205,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0304419X14000572"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2014.07.004","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2014.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}